Integration of Pharmaceutical Discovery and Development Case Histories /

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Borchardt, Ronald T. (Επιμελητής έκδοσης), Freidinger, Roger M. (Επιμελητής έκδοσης), Sawyer, Tomi K. (Επιμελητής έκδοσης), Smith, Philip L. (Επιμελητής έκδοσης)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Boston, MA : Springer US, 1998.
• Σειρά: Pharmaceutical Biotechnology, 11
• Θέματα: Life sciences.; Biochemistry.; Animal physiology.; Life Sciences.; Animal Physiology.; Biochemistry, general.

 In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and metabolic/pharmacokinetic (e. g. , metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g. , medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g. , analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the sci- tific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug d- covery. In the first chapter, Ralph Hirschmann provides a historical perspective of why this paradigm shift in drug discovery has occurred. 

 Renin Inhibitors -- The Discovery and Development of Angiotensin II Antagonists -- Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor -- Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707 -- Endothelin Receptor Antagonists -- LHRH Antagonists -- LHRH Agonists -- Discovery and Development of Somatostatin Agonists -- Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors -- The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development -- De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule -- Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate -- Famciclovir -- The Use of Esters as Prodrugs for Oral Delivery of ?-Lactam Antibiotics -- Hematoregulators -- Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5?-Reductase -- Discovery of a Potent and Selective ?1A Antagonist -- Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2 -- The Anxieties of Drug Discovery and Development -- CI-1015 -- Orally Active Nonpeptide CCK-A Agonists -- Orally Active Growth Hormone Secretagogues -- Dorzolamide, a 40-Year Wait -- Discovery and Development of Novel Melanogenic Drugs.